Quetiapine Augmentation in Severe Obsessive Compulsive Disorder

AstraZeneca

Status and phase: Completed; Phase 3

Conditions: Obsessive Compulsive Disorder

Treatments: Drug: SSRI/Clomipramine; Drug: quetiapine fumarate

Study type: Interventional

Funder types: Industry

Identifiers

NCT00254735

5077/9059

D1441C09059

Details and patient eligibility

About

The purpose of the study is to evaluate the efficacy of quetiapine or placebo added to baseline treatment of SSRI/clomipramine for the treatment of OCD in adult subjects.

Enrollment: 44 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent, men and women aged ³18 to £65 years with diagnosis of OCD, at least 12 weeks of treatment with SSRI or clomipramine

Exclusion criteria

• Substance abuse or dependence, female patients who are pregnant, lactating or at risk of pregnancy, known intolerance or lack of response to quetiapine, use of antihypertensive medication with changing doses

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind